Jiangsu Hengrui Medicine Co Ltd (600276):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Jiangsu Hengrui Medicine Co Ltd (600276) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10144
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its product portfolio includes antineoplastic products, anti-tumor drugs, surgical drugs and contrast agents. The company offers products in central nervous system (CNS), musculoskeletal, metabolic, hematologic, infection, respiratory, cardiovascular, dermatology, gastrointestinal, cancer and other areas. Jiangsu Hengrui has manufacturing and R&D facilities in Shanghai, Chengdu, Suzhou and Lianyungang, China. The company offers its products through sales and distribution network spread across China. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

Jiangsu Hengrui Medicine Co Ltd (600276) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Jiangsu Hengrui Medicine Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
LSK BioPharma and Jiangsu Hengrui Medicine Enter into Agreement 11
Jiangsu Hengrui Medicine Enters into Research Agreement with University of Texas MD Anderson Cancer Center 12
Jiangsu Hengrui Medicine to Form Partnership With Albert Einstein College of Medicine 13
MabSpace Biosciences Enters into Co-Development Agreement with Jiangsu Hengrui Medicine 14
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 15
Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 16
Licensing Agreements 17
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 17
Arcutis Enters into Option and License Agreement with Jiangsu Hengrui Medicine 18
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Oncolys BioPharma 19
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 20
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 21
Jiangsu Hengrui Medicine Co Ltd – Key Competitors 22
Jiangsu Hengrui Medicine Co Ltd – Key Employees 23
Jiangsu Hengrui Medicine Co Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Jiangsu Hengrui Medicine Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Jiangsu Hengrui Medicine Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
LSK BioPharma and Jiangsu Hengrui Medicine Enter into Agreement 11
Jiangsu Hengrui Medicine Enters into Research Agreement with University of Texas MD Anderson Cancer Center 12
Jiangsu Hengrui Medicine to Form Partnership With Albert Einstein College of Medicine 13
MabSpace Biosciences Enters into Co-Development Agreement with Jiangsu Hengrui Medicine 14
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 15
Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 16
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 17
Arcutis Enters into Option and License Agreement with Jiangsu Hengrui Medicine 18
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Oncolys BioPharma 19
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 20
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 21
Jiangsu Hengrui Medicine Co Ltd, Key Competitors 22
Jiangsu Hengrui Medicine Co Ltd, Key Employees 23
Jiangsu Hengrui Medicine Co Ltd, Subsidiaries 24
Jiangsu Hengrui Medicine Co Ltd, Joint Venture 24

List of Figures
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Jiangsu Hengrui Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Jiangsu Hengrui Medicine Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Jiangsu Hengrui Medicine Co Ltd (600276):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pebblebrook Hotel Trust:企業のM&A・事業提携・投資動向
    Pebblebrook Hotel Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pebblebrook Hotel Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • Bristol-Myers Squibb Co (BMY)-医療機器分野:企業M&A・提携分析
    Summary Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is in cancer, cardiovascular, immunoscience and …
  • Information Analysis Inc (IAIC):企業の財務・戦略的SWOT分析
    Summary Information Analysis Inc (IAI) is a technology company that offers technical solutions. The company offers IT services such as legacy mainframe modernization, database conversion and migration, electronic forms conversion, ebusiness and web based solutions, integrated tablet and mobile appli …
  • Panoro Energy ASA (PEN):企業の財務・戦略的SWOT分析
    Summary Panoro Energy ASA (Panoro) is an independent oil and gas exploration and development company that explores, develops and produces oil and gas properties in Brazil and West Africa. The company holds interests in production and exploration assets in Santos and Camamu Almada basins in Brazil. I …
  • The Medicines Company (MDCO)-医療機器分野:企業M&A・提携分析
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products, namely, Angiomax (bivalirudin), Orbactiv (oritavancin), Minocin (minocycl …
  • RigNet Inc (RNET):企業の財務・戦略的SWOT分析
    RigNet Inc (RNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Integra LifeSciences Holdings Corporation:企業の戦略・SWOT・財務情報
    Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • New Look Retail Group Limited:企業の戦略・SWOT・財務情報
    New Look Retail Group Limited - Strategy, SWOT and Corporate Finance Report Summary New Look Retail Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • 23andMe Inc:医療機器:M&Aディール及び事業提携情報
    Summary 23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. Its service portfolio includes clinical development, research and development, ancestry service …
  • Linn Energy, LLC:企業の戦略・SWOT・財務情報
    Linn Energy, LLC - Strategy, SWOT and Corporate Finance Report Summary Linn Energy, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Moberg Pharma AB (MOB):企業の財務・戦略的SWOT分析
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • Evolution Petroleum Corp (EPM):企業の財務・戦略的SWOT分析
    Summary Evolution Petroleum Corp (EPC), a subsidiary of Esrey Resources Ltd, is an oil and gas company that acquires and explores crude oil and natural gas properties. The company explores for oil, liquefied gas, natural gas, and gas reserves in Delhi field CO2-EOR project. It offers GARP or gas ass …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Petroleo Brasileiro SA (PETR4):電力:M&Aディール及び事業提携情報
    Summary Petroleo Brasileiro SA (Petrobras) is an integrated oil and gas company. Its major businesses include exploration and production, refining, marketing, trade and transportation of oil and gas. The company also conducts biofuel, petrochemical, natural gas, electricity and chemical businesses, …
  • Abzena Plc (ABZA):企業の財務・戦略的SWOT分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …
  • Ibersol S.G.P.S., S.A.:企業の戦略・SWOT・財務分析
    Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report Summary Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Celsense Inc-医療機器分野:企業M&A・提携分析
    Summary Celsense Inc (Celsense) is a biotechnology company that develops magnetic resonance imaging detection products. The company’s products include v-sense, cell sense and voxel tracker. Its v-sense product is used to detect a range of lesions and diseases where inflammation is a hallmark such as …
  • Oxford Immunotec Ltd:企業の製品パイプライン分析
    Summary Oxford Immunotec Ltd (Oxford Immunotec) a subsidiary of Oxford Immunotec Global Plc is a medical device company that offers proprietary tests for immune-regulated conditions. The company offers in vitro diagnostic, T-SPOT CMV Test, C6 Lyme ELISA Test, T-Cell Xtend Reagent. It offers T-SPOT.T …
  • Tokyo Seimitsu Co., Ltd. (7729):企業の財務・戦略的SWOT分析
    Tokyo Seimitsu Co., Ltd. (7729) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆